Shilpa Medicare signs long-term CDMO manufacturing deal with NXI Therapeutics
The partnership covers the entire product lifecycle from early-stage development through commercialization
The partnership covers the entire product lifecycle from early-stage development through commercialization
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
Subscribe To Our Newsletter & Stay Updated